Form 4: BioAtla Director Susan Moran Receives Restricted Stock Unit Award

BioAtla, Inc. Director Susan Moran was granted 23,500 shares of common stock through a restricted stock unit award, increasing her beneficial ownership to 52,307 shares.

Summary

• Susan Moran, a Director of BioAtla, Inc. (BCAB), acquired 23,500 shares of common stock on June 18, 2025.
• The acquisition was a time-based Restricted Stock Unit (RSU) award, with a reported price of $0 per share.
• Following this transaction, Ms. Moran's total beneficial ownership in BioAtla, Inc. stands at 52,307 shares of common stock.
• The RSU award is set to vest as to 100% of the total number of shares on the earlier of June 18, 2026, or the next Company annual meeting of stockholders.
• Vesting of the RSU is contingent upon Ms. Moran's continued service to the company through the vesting date.

Sentiment

Score: 6

Explanation: A routine RSU grant to a director, which is a positive for aligning interests but not a significant market-moving event on its own.

Positives

• The grant of Restricted Stock Units (RSUs) to a director helps align their long-term interests with those of the shareholders.
• An increase in a director's beneficial ownership demonstrates continued commitment and confidence in the company's future.

Risks

• The vesting of the 23,500 Restricted Stock Units is subject to Susan Moran's continued service to BioAtla, Inc. through the vesting date, meaning the shares could be forfeited if her service ceases prematurely.

Future Outlook

The RSU award is structured to vest in the future, either by June 18, 2026, or the next annual meeting, contingent on the director's continued service, indicating an expectation of ongoing board involvement and alignment with long-term company performance.

Industry Context

This transaction represents a standard equity compensation practice for directors in publicly traded biotechnology companies, designed to align their financial interests with the long-term performance of the company and shareholder returns.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units (RSUs), are a common and widely accepted form of non-cash compensation for directors across various industries, including the biotechnology sector.
• The specific grant size of 23,500 shares would typically be evaluated against director compensation packages at comparable-sized biotechnology firms to determine if it aligns with industry norms, though this document does not provide such comparative data.

Related Party Transactions

• The RSU grant to Susan Moran, a director, constitutes a transaction with a related party, which is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• Continued service of Susan Moran through the vesting date for the RSU award.
• Vesting of 23,500 RSU shares on the earlier of June 18, 2026, or the next Company annual meeting of stockholders.

Key Dates

Recommendation

Keywords

BioAtla, BCAB, Susan Moran, Form 4, SEC filing, Restricted Stock Units, RSU, Director compensation, equity award, insider transaction, beneficial ownership